The Next Chapter In IgAN’s ‘Beautiful Story’ Could Be Full Approval
US FDA lauds collaborative development of surrogate endpoint that allowed for accelerated approval of the first two drugs for the rare kidney disease. The program was presented as an example of novel endpoints for rare diseases at a Duke/FDA workshop.
